January 10 | 2025 Correction: 2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE Read more
January 10 | 2025 2CUREX APPOINTS MANGOLD CORPORATE FINANCE TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE Read more
May 7 | 2024 2CUREX AB (PUBL) HAS DECIDED TO APPLY FOR A DELISTING OF ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET IN STOCKHOLM – EXPECTED LAST DAY OF TRADING BY END OF JUNE Read more
March 16 | 2024 2CUREX AB (PUBL) PROVIDES AN UPDATE ON ITS FINANCIAL POSITION AND CURRENT OPERATIONS Read more
October 26 | 2023 Strategy update: Leapfrogging to the decentralization of IndiTreat® testing through full focus on automation Read more
October 3 | 2023 2cureX will be holding its Q3 2023 online presentation with a Q&A session on October 26, 2023 at 20.00 (CET). Read more
July 5 | 2023 Invitation to 2cureX Q2 update and Q&A session on July 12, 2023 at 20.00 (CET) Read more
May 11 | 2023 Positive IndiTreat® trial results published in highly recognized scientific journal. Read more
April 12 | 2023 2cureX has received a grant from the Innovation Fund Denmark to support clinical development of a novel IndiTreat® product. Read more
April 10 | 2023 Invitation to 2cureX Q1 update and Q&A session on April 12, 2023 at 20.00 (CET) Read more
April 6 | 2023 2cureX strengthens its IndiTreat® automation project with a prestigious grant from the German Federal Ministry of Education and Research Read more